“Sermes CRO is committed to investing in the development of specific and technological areas”

From Sermes CRO years ago, we saw how this process came to stay and we bet on it. We invest in teams of specialized people to be able to create our own solutions and manage the information in an autonomous way. Nowadays, we have the necessary tools to give all kinds of services from our CRO/E-cro of high quality, budgetary efficiency and in the shortest time.

Sermes CRO: AEMPS approves the NC1 advance therapy drug for patients with chronic traumatic medullary injury

The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.